

INFECTION CONTROL^{AND}

HOSPITAL EPIDEMIOLOGY

Volume 9, Number 7 • July 1988

EDITORIAL

From Ritual to Reason and Back Again: OSHA and the Evolution of Infection Control

William M. Valenti, MD

SPECIAL ARTICLE

Infection Control in Latin America

Donald A. Goldmann, MD; Fernando Otaiza, MD;
Samuel R. Ponce de Leon, MD, MSc; Idis Faingezicht Gutman, MD

ORIGINAL ARTICLES

Nosocomial Respiratory Tract Colonization and Infection with Aminoglycoside-Resistant *Acinetobacter calcoaceticus* var *antitratu*s: Epidemiologic Characteristics and Clinical Significance

James E. Peacock, Jr., MD; LuAnne Sorrell, RN, CIC; Frank D. Sottile, MD;
Loraine E. Price, BSN, CIC; William A. Rutala, PhD, MPH

Description of Case-Mix Adjusters by the Severity of Illness Working Group of The Society of Hospital Epidemiologists of America (SHEA)

Peter A. Gross, MD; B. Eugene Beyt, Jr., MD;
Michael D. Decker, MD, MPH; Richard A. Garibaldi, MD;
Walter J. Hierholzer, Jr., MD; William R. Jarvis, MD;
Elaine Larson, RN, PhD; Bryan Simmons, MD; William E. mScheckler, MD;
Lorraine M. Harkavy, RN, MS

Introduction of a Plasmid Encoding the OHIO-1 β -Lactamase to an Intermediate Care Ward by Patient Transfer

David M. Shlaes, MD, PhD; Charlotte A. Currie-McCumber;
Mary-Helen Lehman

The Official Journal of The Society of Hospital Epidemiologists of America


Recommended by all major scope manufacturers

Sporicidin[®] Requires No Heat

Compare for 100% TUBERCULOCIDAL ACTIVITY

	Temperature	Immersion Time	Dilution	Reuse Life
Sporicidin[®] (EPA Reg. No. 8383-5)	68°F and above (True Room Temperature)	10 Minutes	1:16	30 Days
CIDEX[®] (EPA Reg. No. 7078-1)	77°F Requires Heat	45 Minutes	Full Strength	14 Days

100% Hospital Level
Disinfection for
instruments and
equipment in the
O.R. and
respiratory therapy



Sporicidin[®]
INTERNATIONAL

12000 Old Georgetown Road • Rockville, MD 20852

For Information: 1-800-424-3733

INFECTION CONTROL AND HOSPITAL EPIDEMIOLOGY

EDITORIAL	From Ritual to Reason and Back Again: OSHA and the Evolution of Infection Control	289
	William M. Valenti, MD	
SPECIAL ARTICLE	Infection Control in Latin America	291
	Donald A. Goldmann, MD; Fernando Otaiza, MD; Samuel R. Ponce de Leon, MD, MSc; Idis Faingezicht Gutman, MD	
ORIGINAL ARTICLES	Nosocomial Respiratory Tract Colonization and Infection with Aminoglycoside-Resistant <i>Acinetobacter calcoaceticus</i> var <i>antitratu</i>s: Epidemiologic Characteristics and Clinical Significance	302
	James E. Peacock, Jr., MD; LuAnne Sorrell, RN, CIC; Frank D. Sottile, MD; Loraine E. Price, RSN, CIC; William A. Rutala, PhD, MPH	
	Description of Case-Mix Adjusters by the Severity of Illness Working Group of The Society of Hospital Epidemiologists of America (SHEA)	309
	Peter A. Gross, MD; B. Eugene Beyt, Jr., MD; Michael D. Decker, MD, MPH; Richard A. Garibaldi, MD; Walter J. Hierholzer, Jr., MD; William R. Jarvis, MD; Elaine Larson, RN, PhD; Bryan Simmons, MD; William E. Scheckler, MD; Lorraine M. Harkavy, RN, MS	
	Introduction of a Plasmid Encoding the OHIO-1 P-Lactamase to an Intermediate Care Ward by Patient Transfer	317
	David M. Shlaes, MD, PhD; Charlotte A. Currie-McCumber; Mary-Helen Lehman	
SPECIAL SECTIONS	Readers' Forum: Hospital Infection Surveillance in the United Kingdom	320
	G.A.J. Ayliffe, MD, FRCPath	
	Clinical Pharmacology of Antibiotics: Sulbactam/Ampicillin	323
	Francine R. Salamone, RPh, PharmD	
	Product Commentary: Searchin'	328
	Sue Crow, MSN, RN, CIC	
	Topics in Clinical Epidemiology: Mortality Rates as a Quality Indicator: A Simple Answer to a Complex Question	330
	William B. Crede, MD; Walter J. Hierholzer, Jr., MD	
DEPARTMENTS	Letters to the Editor 286	Calendar of Events 336
	SHEA Newsletter 333	Information for Authors Cover 3
	Classified Marketplace 335	

The ideas and opinions expressed by contributing authors do not necessarily reflect those of the editors or publisher.

Publisher: Infection Control and Hospital Epidemiology (ISSN-0195-9417) is published monthly by SLACK Incorporated 6900 Grove Road Thorofare New Jersey 08086 Telephone (609) 848-1000

Copyright 1988: 411 rights reserved No part of this publication may be reproduced without written permission from the publisher

Subscriptions. Requests should be addressed to the publisher (except Japan) In Japan contact Woodbell Incorporated 4-22-11 Kitakasai Edogawaku Tokyo 134 Japan Subscription rates in the US and possessions Individual One year—\$45 00; Two years—\$75 00 Three years—\$105 00 Institutional One year—\$60 00; Two years—\$100 00 Three years—\$140 00 Canada \$15 00 additional each year all other countries \$25 00 additional each year Single copies of current issues may be obtained for \$7 00, United States and possessions \$13 00 all other countries

Change of address: Notice should be sent to the publisher six weeks in advance of effective date Include old and new addresses with zip codes The publisher cannot accept responsibility for undelivered copies Second-class postage is paid at Thorofare, New Jersey 08086 and additional entry points **Postmaster:** Send address changes to SLACK Incorporated, 6900 Grove Road, Thorofare, NJ 08086

As of Volume 1, Number 1 INFECTION CONTROL AND HOSPITAL EPIDEMIOLOGY is listed in *Index Medicus*, *Current Contents—Clinical Practice*, *Hospital Literature Index* and *Cumulative Index to Nursing and Allied Health Literature*

EDITORIAL OFFICES

Vanderbilt University School of Medicine
 A-1131 Medical Center North
 Nashville, TN 37232-2637
 (615) 343-1095; (615) 343-1882 (FAX)
 Email: iche@mcmail.vanderbilt.edu

EDITOR

Michael D. Decker, MD, MPH

MANAGING EDITOR

Susan Cantrell

STATISTICAL EDITOR

Beverly G. Mellen, PhD

SENIOR ASSOCIATE EDITORS

C. Glen Mayhall, MD

Gina Pugliese, RN, MS

William Schaffner, MD

ASSOCIATE EDITORS

Donald A. Goldmann, MD

Didier Pittet, MD, MS

Andreas Widmer, MD, MS

SECTION EDITORS**Beyond Infection Control:****The New Hospital Epidemiology**

Bryan P. Simmons, MD

Stephen B. Kritchevsky, PhD

Memphis, Tennessee

Wing Hong Seto, MD

Hong Kong

Disinfection and Sterilization

William A. Rutala, PhD, MPH

Chapel Hill, North Carolina

Emerging Infectious Diseases

Larry J. Strausbaugh, MD

Portland, Oregon

Robert W. Pinner, MD

Atlanta, Georgia

From the Laboratory

Marcus Zervos, MD

Royal Oak, Michigan

Fred C. Tenover, PhD

Atlanta, Georgia

Information Management

John A. Sellick, DO

Buffalo, New York

The International Perspective

Mary D. Nettleman, MD, MS

Richmond, Virginia

Issues in Surgery

James T. Lee, MD, PhD

St. Paul, Minnesota

Medical News

Gina Pugliese, RN, MS

Chicago, Illinois

Martin S. Favero, PhD

Irvine, California

Practical Healthcare Epidemiology

Loreen A. Herwaldt, MD

Iowa City, Iowa

SHEA News

Murray D. Batt, MD

Clarksburg, West Virginia

Statistics for Hospital Epidemiology

David Birnbaum, PhD, MPH

Sidney, British Columbia, Canada

Topics in Long-Term Care

Philip W. Smith, MD

Omaha, Nebraska

Topics in Occupational Medicine

David Weber, MD, MPH

Chapel Hill, North Carolina

INFECTION CONTROL AND HOSPITAL EPIDEMIOLOGY[®]

EDITORIAL ADVISORY BOARD

- Jacques F. Acar, MD Paris, France
 J. Wesley Alexander, MD Cincinnati, Ohio
 Paul Arnow, MD Chicago, Illinois
 Graham A.J. Ayliffe, MD Birmingham, United Kingdom
 Neil L. Barg, MD Yakima, Washington
 Elizabeth Ann Bolyard, RN, MPH, CIC Atlanta, Georgia
 John M. Boyce, MD Providence, Rhode Island
 Professor Dr. Ilja Braveny Munich, Federal Republic of Germany
 Charles Bryan, MD Columbia, South Carolina
 Christian Brun-Buisson, MD Creteil, France
 Donald E. Craven, MD Boston, Massachusetts
 Sue Crow, MSN, RN, CIC Shreveport, Louisiana
 Franz Daschner, MD Freiburg, Federal Republic of Germany
 Leigh G. Donowitz, MD Charlottesville, Virginia
 Charles E. Edmiston, Jr., PhD Milwaukee, Wisconsin
 Theodore C. Eickhoff, MD Denver, Colorado
 Bruce Farber, MD Manhasset, New York
 Victoria J. Fraser, MD St. Louis, Missouri
 Peter C. Fuchs, MD, PhD Black Butte, Oregon
 Richard A. Garibaldi, MD Farmington, Connecticut
 Velvl Greene, PhD, MPH Beer Sheva, Israel
 Robert Gaynes, MD Atlanta, Georgia
 David W. Gregory, MD Nashville, Tennessee
 David K. Henderson, MD Bethesda, Maryland
 Peter N.R. Heseltine, MD Los Angeles, California
 Karen Hoffmann, RN, CIC, MS Chapel Hill, North Carolina
 Marguerite McMillan Jackson, RN, PhD San Diego, California
 Janine Jagger, MPH, PhD Charlottesville, Virginia
 William R. Jarvis, MD Atlanta, Georgia
 Douglas S. Kernodle, MD Nashville, Tennessee
 Robert H. Latham, MD Nashville, Tennessee
 Lewis B. Lefkowitz, MD Nashville, Tennessee
 Hsieh-Shong Leu, MD, MSc Taipei, Taiwan
 Jack Levy, MD Brussels, Belgium
 Victor Lorian, MD Bronx, New York
 Dennis G. Maki, MD Madison, Wisconsin
 Professor Dr. Walter Marget Munich, Federal Republic of Germany
 William J. Martone, MD Bethesda, Maryland
 Allison McGeer, MD Toronto, Ontario, Canada
 John E. McGowan, Jr., MD Atlanta, Georgia
 Jonathan L. Meakins, MD, DSc Montreal, Quebec, Canada
 Raf Mertens, MD Brussels, Belgium
 Robert R. Muder, MD Pittsburgh, Pennsylvania
 Joseph M. Mylotte, MD, CIC Buffalo, New York
 Lindsay Nicolle, MD Winnipeg, Manitoba, Canada
 Juhani Ojajarvi, MD Helsinki, Finland
 Michael T. Osterholm, PhD, MPH Minneapolis, Minnesota
 Jan Evans Patterson, MD San Antonio, Texas
 Sindy M. Paul, MD Trenton, New Jersey
 Michael A. Pfaller, MD Iowa City, Iowa
 Samuel Ponce de Leon, MD, MSc Mexico City, Mexico
 Isaam Raad, MD Houston, Texas
 Manfred L. Rotter, MD, DipBact Vienna, Austria
 Theodore Sacks, MD Jerusalem, Israel
 William E. Scheckler, MD Madison, Wisconsin
 Kent Sepkowitz, MD New York City, New York
 Denis Spelman, MD Prahran Victoria, Australia
 Michael L. Tapper, MD New York, New York
 Clyde Thornsberry, PhD Brentwood, Tennessee
 Professor Leonid P. Titov Minsk, Republic of Belarus
 Timothy R. Townsend, MD Millwood, Virginia
 Antoni Trilla, MD, PhD Barcelona, Spain
 Professor Wang Shu-Qun Beijing, People's Republic of China
 J. John Weems, Jr., MD Greenville, South Carolina
 Robert A. Weinstein, MD Chicago, Illinois
 Professor Dr. W. Weuffen Greifswald, Federal Republic of Germany
 Sergio B. Wey, MD São Paulo, Brazil
 Rebecca Wurtz, MD Evanston, Illinois

SLACK Incorporated

6900 Grove Road
 Thorofare, New Jersey 08086
 (609) 848-1000

Vice President/Group Publisher

Richard N. Roash

Publisher

John C. Carter

Editorial Director

Jennifer Kilpatrick

Production Editor

Shirley P. Strunk, ELS

Assistant Editor

Eileen C. Anderer

Circulation Manager

Lester J. Robeson, CCCC

Production Director

Christine Malin

Production Coordinator

Joanne Patterson

Publishing Director/ Advertising

Wayne McCourt

Pharmaceutical Group Sales Director

Michael LoPresti

Advertising Sales Representative

Jennine Kane

Classified/Recruitment Sales Manager

Michele Burch

What is it?

Spread by blood or sexual contact.

300,000 new cases will occur in the U.S. this year.

Hemophiliacs, Asian immigrants, heterosexuals with multiple partners, male homosexuals, IV drug users, and health-care personnel are at highest risk.

See the following page for a Brief Summary of Prescribing Information for RECOMBIVAX HB[®] (Hepatitis B Vaccine [Recombinant], MSD).



Copyright © 1988 by MERCK & CO., Inc

RECOMBIVAX HB*

[Hepatitis B Vaccine (Recombinant), MSD]

INDICATIONS AND USAGE

RECOMBIVAX HB is indicated for immunization against infection caused by all known subtypes of hepatitis B virus.

RECOMBIVAX HB will not prevent hepatitis caused by other agents, such as hepatitis A virus, non-A, non-B hepatitis viruses, or other viruses known to infect the liver.

Vaccination is recommended in persons of all ages who are or will be at increased risk of infection with hepatitis B virus. In areas with high prevalence of infection, most of the population are at risk of acquiring hepatitis B infection at a young age. Therefore, vaccination should be targeted to prevent such transmission. In areas of low prevalence, vaccination should be limited to those who are in groups identified as being at increased risk of infection.

CONTRAINDICATIONS

Hypersensitivity to yeast or any component of the vaccine.

WARNINGS

Patients who develop symptoms suggestive of hypersensitivity after an injection should not receive further injections of RECOMBIVAX HB (see CONTRAINDICATIONS).

RECOMBIVAX HB*

[Hepatitis B Vaccine (Recombinant), MSD]

Because of the long incubation period for hepatitis B, it is possible for unrecognized infection to be present at the time RECOMBIVAX HB is given. RECOMBIVAX HB may not prevent hepatitis B in such patients.

PRECAUTIONS

General

As with any percutaneous vaccine, epinephrine should be available for immediate use should an anaphylactoid reaction occur.

Any serious active infection is reason for delaying use of RECOMBIVAX HB except when, in the opinion of the physician, withholding the vaccine entails a greater risk.

Caution and appropriate care should be exercised in administering RECOMBIVAX HB to individuals with severely compromised cardiopulmonary status or to others in whom a febrile or systemic reaction could pose a significant risk.

Pregnancy

Pregnancy Category C. Animal reproduction studies have not been conducted with RECOMBIVAX HB. It is also not known whether RECOMBIVAX HB can cause fetal harm when administered to a pregnant woman or can affect

RECOMBIVAX HB*

[Hepatitis B Vaccine (Recombinant), MSD]

reproductive capacity. RECOMBIVAX HB should be given to a pregnant woman only if clearly needed.

Nursing Mothers

It is not known whether RECOMBIVAX HB is excreted in human milk. Because many drugs are excreted in human milk, caution should be exercised when RECOMBIVAX HB is administered to a nursing woman.

Pediatric Use

RECOMBIVAX HB has been shown to be usually well tolerated and highly immunogenic in infants and children of all ages. Newborns also respond well; maternally transferred antibodies do not interfere with the active immune response to the vaccine. See DOSAGE AND ADMINISTRATION for recommended pediatric dosage and for recommended dosage for infants born to HBsAg positive mothers.

ADVERSE REACTIONS

RECOMBIVAX HB is generally well tolerated. No serious adverse reactions attributable to the vaccine have been reported during the course of clinical trials. No serious hypersensitivity reactions have been reported. No adverse experiences

RECOMBIVAX HB*

[Hepatitis B Vaccine (Recombinant), MSD]

were reported during clinical trials which could be related to changes in the titers of antibodies to yeast. As with any vaccine, there is the possibility that broad use of the vaccine could reveal adverse reactions not observed in clinical trials.

In a group of studies, 3258 doses of vaccine were administered to 1252 healthy adults who were monitored for 5 days after each dose. Injection site and systemic complaints were reported following 17% and 15% of the injections, respectively.

The following adverse reactions were reported.

Incidence Equal to or Greater than 1% of Injections

LOCAL REACTION (INJECTION SITE)

Injection site reactions consisting principally of soreness and including pain, tenderness, pruritus, erythema, ecchymosis, swelling, warmth, and nodule formation.

BODY AS A WHOLE

The most frequent systemic complaints include fatigue/weakness, headache, fever ($\geq 100^{\circ}\text{F}$), malaise.

DIGESTIVE SYSTEM

Nausea, diarrhea.

Hepatitis B.

It can be prevented.
A vaccine is available.

Help eliminate the risk...

Recombivax HB[®] (Hepatitis B Vaccine [Recombinant] | MSD)

RECOMBIVAX HB is contraindicated in the presence of hypersensitivity to yeast or any other component of the vaccine.

See below for a Brief Summary of Prescribing Information for RECOMBIVAX HB.

RECOMBIVAX HB[®] (Hepatitis B Vaccine [Recombinant], MSD)

RESPIRATORY SYSTEM

Pharyngitis, upper respiratory infection.

Incidence Less than 1% of Injections

BODY AS A WHOLE

Sweating; achiness; sensation of warmth; lightheadedness, chills; flushing.

DIGESTIVE SYSTEM

Vomiting; abdominal pain/cramps; dyspepsia; diminished appetite.

RESPIRATORY SYSTEM

Rhinitis, influenza; cough.

NERVOUS SYSTEM

Vertigo/dizziness; paresthesia.

INTEGUMENTARY SYSTEM

Pruritus, rash (non-specific), angioedema, urticaria.

MUSCULOSKELETAL SYSTEM

Arthralgia including monoarticular; myalgia; back pain; neck pain; shoulder pain; neck stiffness.

HEMIC/LYMPHATIC SYSTEM

Lymphadenopathy.

PSYCHIATRIC/BEHAVIORAL

Insomnia/disturbed sleep.

RECOMBIVAX HB[®] (Hepatitis B Vaccine [Recombinant], MSD)

SPECIAL SENSES

Ears/eye.

UROGENITAL SYSTEM

Dysuria.

CARDIOVASCULAR SYSTEM

Hypotension.

Potential ADVERSE EFFECTS

In addition, a variety of adverse effects, not observed in clinical trials with RECOMBIVAX HB, have been reported with HEPTAVAX-B[®] (Hepatitis B Vaccine, MSD) (plasma-derived hepatitis B vaccine). Those listed below are to serve as alerting information to physicians:

Hypersensitivity: An apparent hypersensitivity syndrome of delayed onset has been reported days to weeks after vaccination. This has included the following findings: arthritis (usually transient), fever, and dermatologic reactions such as urticaria, erythema multiforme, or ecchymoses.

Nervous System: Neurological disorders such as optic neuritis, myelitis including transverse myelitis, acute radiculoneuropathy including Guillain-Barré syndrome, peripheral neuropathy including Bell's palsy and herpes zoster.

Hematologic: Thrombocytopenia.

RECOMBIVAX HB[®] (Hepatitis B Vaccine [Recombinant], MSD)

Special Senses: Tinnitus, visual disturbances.

DOSAGE AND ADMINISTRATION

Do not inject intravenously or intradermally.

RECOMBIVAX HB is for intramuscular injection. The **deltoid muscle** is the preferred site for intramuscular injection in adults. Data suggest that injections given in the buttocks frequently are given into fatty tissue instead of into muscle. Such injections have resulted in a lower seroconversion rate than was expected. The **anterolateral thigh** is the recommended site for intramuscular injection in infants and young children.

RECOMBIVAX HB may be administered subcutaneously to persons at risk of hemorrhage following intramuscular injections. However, when other aluminum-adsorbed vaccines have been administered subcutaneously, an increased incidence of local reactions including subcutaneous nodules has been observed. Therefore, subcutaneous administration should be used only in persons (e.g., hemophiliacs) at risk of hemorrhage following intramuscular injections.

The immunization regimen consists of 3 doses of vaccine. The volume of vaccine to be given on each occasion is as follows:

RECOMBIVAX HB[®] (Hepatitis B Vaccine [Recombinant], MSD)

Group	Formulation	Initial	1 month	6 months
Younger Children (Birth to 10 years of age)	Pediatric 5 mcg/0.5 mL	0.5 mL	0.5 mL	0.5 mL
Adults and Older Children	Adult 10 mcg/1.0 mL	1.0 mL	1.0 mL	1.0 mL

Whenever revaccination or administration of a booster dose is appropriate, RECOMBIVAX HB may be used.

For dosage for infants born of HBsAg positive mothers and for dosage for known or presumed exposure to HBsAg, see the Prescribing Information.

The vaccine should be used as supplied; no dilution or reconstitution is necessary. The full recommended dose of the vaccine should be used.

Storage

Store vials at 2–8°C (35.6–46.4°F). Storage above or below the recommended temperature may reduce potency.

Do not freeze since freezing destroys potency.

For more detailed information, consult your MSD Representative or see Prescribing Information, Merck Sharp & Dohme, Division of Merck & Co., Inc., West Point, PA 19486. J7RX04 (201)